XML 44 R48.htm IDEA: XBRL DOCUMENT
v3.20.1

Commitments and Contingencies - (CFTR Activators and Inhibitors) - Additional Information (Detail) - CFTR Activators and Inhibitors - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended | 37 Months Ended
--- | --- | --- | --- | ---
Mar. 31, 2019 | Mar. 31, 2020 | Dec. 31, 2017 | Mar. 31, 2020
Commitments and Contingencies [Line Items] |  |  |  |
Future percentage of royalty payments based net sales |  | single-digit |  |
Development and milestone obligations paid to third party |  |  |  | $ 1,200
Regulatory Approval Milestone |  |  |  |
CFTR activators and inhibitors |  |  |  |
Possible future milestone payments |  | $ 12,200 |  |
Future Regulatory Approval And Sales Milestones |  |  |  |
CFTR activators and inhibitors |  |  |  |
Possible future milestone payments |  | 33,000 |  |
Development And Milestone Payment, Conclusion Of Phase I Study |  |  |  |
Commitments and Contingencies [Line Items] |  |  |  |
Development and milestone obligations paid to third party | $ 200 |  | $ 1,000 |
CFTR activators and inhibitors |  |  |  |
Possible future milestone payments |  | 350 |  |
Maximum | Development And Milestone Payment, Conclusion Of Phase I Study |  |  |  |
CFTR activators and inhibitors |  |  |  |
Possible future milestone payments |  | $ 1,100 |  |

X
- Definition CFTR activators and inhibitors [Abstract] + References No definition available. + Details
Name: | vnda_CftrActivatorsAndInhibitorsAbstract
Namespace Prefix: | vnda_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Commitments and contingencies. + References No definition available. + Details
Name: | vnda_CommitmentsAndContingenciesLineItems
Namespace Prefix: | vnda_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Development And Milestone Obligations Paid To Third Party + References No definition available. + Details
Name: | vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty
Namespace Prefix: | vnda_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones. + References No definition available. + Details
Name: | vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
Namespace Prefix: | vnda_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Future Percentage Of Royalty Payments Based On Net Sales. + References No definition available. + Details
Name: | vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales
Namespace Prefix: | vnda_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=vnda_CftrActivatorsAndInhibitorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_RegulatoryApprovalMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_FutureRegulatoryApprovalAndSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |